Cargando…

HER2-low breast cancer shows a lower immune response compared to HER2-negative cases

Currently, the human epidermal growth factor receptor 2 (HER2) status of breast cancer is classified dichotomously as negative or positive to select patients for HER2-targeted therapy. However, with the introduction of novel treatment options, it is important to get more insight in the biology of ca...

Descripción completa

Detalles Bibliográficos
Autores principales:	van den Ende, Nadine S., Smid, Marcel, Timmermans, Annemieke, van Brakel, Johannes B., Hansum, Tim, Foekens, Renée, Trapman, Anita M. A. C., Heemskerk-Gerritsen, Bernadette A. M., Jager, Agnes, Martens, John W. M., van Deurzen, Carolien H. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334272/ https://www.ncbi.nlm.nih.gov/pubmed/35902644 http://dx.doi.org/10.1038/s41598-022-16898-6

Ejemplares similares

Transcriptomic Properties of HER2+ Ductal Carcinoma In Situ of the Breast Associate with Absence of Immune Cells
por: Agahozo, Marie Colombe, et al.
Publicado: (2021)

Prognostic significance of nuclear expression of UMP-CMP kinase in triple negative breast cancer patients
por: Liu, Ning Qing, et al.
Publicado: (2016)

Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor()
por: Beije, Nick, et al.
Publicado: (2016)

The Prevalence of CD146 Expression in Breast Cancer Subtypes and Its Relation to Outcome
por: de Kruijff, Ingeborg E., et al.
Publicado: (2018)

Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer
por: Verschoor, Noortje, et al.
Publicado: (2023)

Loss of Y-Chromosome during Male Breast Carcinogenesis
por: Agahozo, Marie Colombe, et al.
Publicado: (2020)

Somatic mutations and copy number variations in breast cancers with heterogeneous HER2 amplification
por: Van Bockstal, Mieke R., et al.
Publicado: (2020)

Metabotropic glutamate receptor 1 is associated with unfavorable prognosis in ER-negative and triple-negative breast cancer
por: Bastiaansen, Anna E. M., et al.
Publicado: (2020)

Ferritin Heavy Chain in Triple Negative Breast Cancer: A Favorable Prognostic Marker that Relates to a Cluster of Differentiation 8 Positive (CD8+) Effector T-cell Response
por: Liu, Ning Qing, et al.
Publicado: (2014)

Real-world data of HER2-low metastatic breast cancer: A population based cohort study
por: Holthuis, Emily I., et al.
Publicado: (2022)

Carcinoma in situ to invasive breast cancer
por: van Deurzen, Carolien H.M., et al.
Publicado: (2015)

Real-world data on discordance between estrogen, progesterone, and HER2 receptor expression on diagnostic tumor biopsy versus tumor resection material
por: Berghuis, A. M. Sofie, et al.
Publicado: (2019)

Tumor-agnostic ctDNA levels by mFAST-SeqS in first-line HR-positive, HER2 negative metastatic breast cancer patients as a biomarker for survival
por: Verschoor, Noortje, et al.
Publicado: (2023)

Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review
por: van den Ende, Nadine S., et al.
Publicado: (2023)

HER2 signaling regulates HER2 localization and membrane retention
por: Jeong, Jaekwang, et al.
Publicado: (2017)

Proteomic characterization of microdissected breast tissue environment provides a protein‐level overview of malignant transformation
por: Braakman, René B. H., et al.
Publicado: (2017)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Majumder, Avisek, et al.
Publicado: (2021)

Association between Acquired Uniparental Disomy and Homozygous Mutations and HER2/ER/PR Status in Breast Cancer
por: Tuna, Musaffe, et al.
Publicado: (2010)

HER kinase inhibition in patients with HER2- and HER3-mutant cancers
por: Hyman, David M., et al.
Publicado: (2018)

Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
por: Atallah, N. M., et al.
Publicado: (2023)

The dynamics of HER2 status in esophageal adenocarcinoma
por: Creemers, Aafke, et al.
Publicado: (2018)

Circular RNA in Chemonaive Lymph Node Negative Colon Cancer Patients
por: van den Berg, Inge, et al.
Publicado: (2021)

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
por: Lipton, Allan, et al.
Publicado: (2013)

Response to HER2 Inhibition in a Patient With Brain Metastasis With EGFR TKI Acquired Resistance and an HER2 Amplification
por: Meedendorp, Arenda D., et al.
Publicado: (2018)

Risk of metachronous contralateral breast cancer in patients with primary invasive lobular breast cancer: Results from a nationwide cohort
por: Akdeniz, Delal, et al.
Publicado: (2022)

Transition probabilities of HER2-positive and HER2-negative breast cancer patients treated with Trastuzumab obtained from a clinical cancer registry dataset
por: Pobiruchin, Monika, et al.
Publicado: (2016)

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
por: Sassen, Andrea, et al.
Publicado: (2008)

Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer
por: Tarantino, P., et al.
Publicado: (2023)

Phosphoserine aminotransferase 1 is associated to poor outcome on tamoxifen therapy in recurrent breast cancer
por: De Marchi, Tommaso, et al.
Publicado: (2017)

Effects of Lapatinib on HER2-Positive and HER2-Negative Canine Mammary Carcinoma Cells Cultured In Vitro
por: Leis-Filho, Antonio Fernando, et al.
Publicado: (2021)

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
por: Horimoto, Yoshiya, et al.
Publicado: (2022)

A novel HER2 gene body enhancer contributes to HER2 expression
por: Liu, Q, et al.
Publicado: (2018)

Association of HER1 and HER2 Gene Variants in the Predisposition of Colorectal Cancer
por: Alanazi, Ibrahim O., et al.
Publicado: (2021)

Preclinical HER-2 Vaccines: From Rodent to Human HER-2
por: Lollini, Pier-Luigi, et al.
Publicado: (2013)

The role of neoadjuvant her2-targeted therapies in her2-overexpressing breast cancers
por: Lemieux, J., et al.
Publicado: (2009)

Using second harmonic generation to predict patient outcome in solid tumors
por: Burke, K., et al.
Publicado: (2015)

HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer
por: Green, Andrew R., et al.
Publicado: (2014)

Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer
por: Han, Sae-Won, et al.
Publicado: (2012)

HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
por: Van Cutsem, Eric, et al.
Publicado: (2014)

Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer
por: Stenehjem, David D, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_30oed076ut1se6b34lhhlbmujf